About IO102-IO103 IO102-IO103 is an investigational off-the-shelf therapeutic cancer vaccine designed to kill both tumor cells and immune-suppressive cells in the tumor microenvironment (TME) by ...
The clinical trials are sponsored by IO Biotech and conducted in collaboration with Merck, which is supplying pembrolizumab. IO Biotech maintains global commercial rights to IO102-IO103. KEYTRUDA® is ...
By Ayako Wakatsuki Pedersen, Ph.D., Senior Vice President of Translational Research at IO Biotech | Making the tumor microenvironment hostile to cancer cells and immune-suppressive cells may transform ...
1 Institute of Cancer, Xinqiao Hospital, Army Medical University, Chongqing, China 2 Department of Respiratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, ...